These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 25562993)

  • 21. [Direct acting oral anticoagulants in venous thromboembolism].
    Walti C; Bächli E
    Praxis (Bern 1994); 2015 Jul; 104(15):771-80. PubMed ID: 26204334
    [No Abstract]   [Full Text] [Related]  

  • 22. Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation.
    Armbruster HL; Lindsley JP; Moranville MP; Habibi M; Khurram IM; Spragg DD; Berger RD; Calkins H; Marine JE
    Ann Pharmacother; 2015 Mar; 49(3):278-84. PubMed ID: 25515868
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: network meta-analysis.
    Alotaibi G; Alsaleh K; Wu C; Mcmurtry MS
    Int Angiol; 2014 Aug; 33(4):301-8. PubMed ID: 25056161
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [New clinical perspectives in the management of oral direct anticoagulant agents].
    Marco P; Zamorano JL; Chana F; Llau JV
    Med Clin (Barc); 2014 Feb; 142(4):171-8. PubMed ID: 23866969
    [No Abstract]   [Full Text] [Related]  

  • 25. New oral anticoagulants: an emergency department overview.
    Wood P
    Emerg Med Australas; 2013 Dec; 25(6):503-14. PubMed ID: 24224462
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Testing the therapeutic equivalence of novel oral anticoagulants for thromboprophylaxis in orthopedic surgery and for prevention of stroke in atrial fibrillation.
    Messori A; Fadda V; Maratea D; Trippoli S; Marinai C
    Int J Clin Pharmacol Ther; 2015 Mar; 53(3):211-9. PubMed ID: 25295718
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The laboratory and the new oral anticoagulants.
    Tripodi A
    Clin Chem; 2013 Feb; 59(2):353-62. PubMed ID: 23043068
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
    Harenberg J; Marx S; Diener HC; Lip GY; Marder VJ; Wehling M; Weiss C
    Int Angiol; 2012 Aug; 31(4):330-9. PubMed ID: 22801398
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Direct oral anticoagulants in the prevention of venous thromboembolism: evidence from major clinical trials.
    Prandoni P; Temraz S; Taher A
    Semin Hematol; 2014 Apr; 51(2):121-30. PubMed ID: 24861796
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The new oral anticoagulants in clinical practice.
    Gonsalves WI; Pruthi RK; Patnaik MM
    Mayo Clin Proc; 2013 May; 88(5):495-511. PubMed ID: 23639500
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Are new oral anticoagulant dosing recommendations optimal for all patients?
    Powell JR
    JAMA; 2015 Mar; 313(10):1013-4. PubMed ID: 25756434
    [No Abstract]   [Full Text] [Related]  

  • 32. Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation.
    Providência R; Marijon E; Albenque JP; Combes S; Combes N; Jourda F; Hireche H; Morais J; Boveda S
    Europace; 2014 Aug; 16(8):1137-44. PubMed ID: 24550347
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Editor's Choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials.
    Kakkos SK; Kirkilesis GI; Tsolakis IA
    Eur J Vasc Endovasc Surg; 2014 Nov; 48(5):565-75. PubMed ID: 24951377
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Bleeding and surgery in the treatment with new oral anticoagulants. The management can be complicated by the lack of specific antidotes].
    Dalén M; Hjemdahl P; Holmström M; Ivert T
    Lakartidningen; 2014 Jun 11-17; 111(24):1064-8. PubMed ID: 25129916
    [No Abstract]   [Full Text] [Related]  

  • 35. Direct oral anticoagulants in the management of venous thromboembolism--evidence from major clinical trials.
    Holy EW; Beer JH
    Semin Hematol; 2014 Apr; 51(2):131-8. PubMed ID: 24861797
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potential impact of new oral anticoagulants on the management of atrial fibrillation-related stroke in primary care.
    Harris K; Mant J
    Int J Clin Pract; 2013 Jul; 67(7):647-55. PubMed ID: 23621153
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Stroke prevention in atrial fibrillation : old and new anticoagulants].
    Darius H; Sommer S
    Herz; 2013 May; 38(3):231-8. PubMed ID: 23632424
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study.
    Banerjee A; Lane DA; Torp-Pedersen C; Lip GY
    Thromb Haemost; 2012 Mar; 107(3):584-9. PubMed ID: 22186961
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Role of new oral anticoagulants in interventional cardiology].
    Brasselet C; Duval S
    Ann Cardiol Angeiol (Paris); 2012 Dec; 61(6):453-6. PubMed ID: 23102941
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [New direct oral anticoagulants and venous thromboprophylaxis].
    Degirmenci SE; Steib A
    Rev Prat; 2013 Sep; 63(7):976-9. PubMed ID: 24167901
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.